Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. New Eng J Med. 2009;361(5):496-509.10.1056/NEJMra0804595Search in Google Scholar

2. Christiophers E, Henseter T. Psoriasis type I and type II as subtypes of non pustular psoriasis. In: Roenigk H, Maibach H, editors. Psoriasis. New York: Dekker; 1990. p. 15-21.Search in Google Scholar

3. Vasků V, Bienertová Vasků J, Pávková Goldbergová M, Vasků A. Three retinoid x receptor gene polymorphism in plaque psoriasis and psoriasis guttata. Dermatology. 2007;214(2):118-24.10.1159/000098569Search in Google Scholar

4. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-50.10.1016/j.jaad.2008.02.039Search in Google Scholar

5. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851-64.10.1016/j.jaad.2008.02.04018423261Open DOISearch in Google Scholar

6. Boker A, Kimball AB, Rolz-Cruz G. Biologicals in the treatment of psoriasis. Curr Opin Investig Drugs. 2007;8(11):939-46.Search in Google Scholar

7. Barlett BL, Tyring SK. Ustekinumab for chronic plaque psoriasis. Lancet. 2008;371(9625):1639-40.10.1016/S0140-6736(08)60702-3Search in Google Scholar

8. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol. 2007;57(6):1059-68.10.1016/j.jaad.2007.07.016Search in Google Scholar

9. Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U. Modulation of CLA, IL-12R, CD40L, and IL-2pα expression and inhibition of IL-12 and IL-23 induced cytokine secretion by CNTO1275. Cell Immunol. 2007;247(1):1-11.10.1016/j.cellimm.2007.06.006Search in Google Scholar

10. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-wk result from a randomised, double-blind, placebo-controlled trial (PHOENIX1). Lancet. 2008;371(9625):1665-74.10.1016/S0140-6736(08)60725-4Search in Google Scholar

11. Steinman L. A brief history of Th17, the first major revision in Th1/Th2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13(2):139-45.10.1038/nm155117290272Open DOISearch in Google Scholar

12. Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: a new therapeutic target in inflammatory dermatosis. J Dermatolog Treat. 2008;19(6):318-26.10.1080/0954663080220666018626814Search in Google Scholar

13. Lebwohl M. Psoriasis. Lancet. 2003;361(9364):1197-204.10.1016/S0140-6736(03)12954-6Search in Google Scholar

14. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25(6):510-8.10.1016/j.clindermatol.2007.08.003Search in Google Scholar

15. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370(9583):272-84.10.1016/S0140-6736(07)61129-5Search in Google Scholar

16. Griffiths CE, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, et al. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol. 2006;24 (1 Suppl 40);72-8.Search in Google Scholar

17. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patient with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX2). Lancet 2008;371(9625):1675-84.10.1016/S0140-6736(08)60726-6Search in Google Scholar

18. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-50. SAME AS REF 310.1016/j.jaad.2008.02.03918423260Search in Google Scholar

19. Ellis CN, Krueger GG; Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effecter T lymphocytes. N Engl J Med. 2001;345(4):248-55.10.1056/NEJM20010726345040311474662Search in Google Scholar

20. Papp KA, Carey W. Psoriasis care. New and emerging pharmacologic trends. J Cutan Med Surg. 2010;14 (3):119-29.10.2310/7750.2010.0903920487672Open DOISearch in Google Scholar

21. Weger W. Current status and new development in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol. 2010;160(4):810-20.10.1111/j.1476-5381.2010.00702.x293598820590580Search in Google Scholar

22. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody. Nat Rev Drug Discov. 2010;9(10):767-74.10.1038/nrd322920811384Open DOISearch in Google Scholar